Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 06:50 AM
November 2025
In this expert-led session, Allysa Saggese, NP, at Weill Cornell Medicine, breaks down the latest evidence and evolving best practices in the diagnosis and management of MASLD and MASH. She explains the 2023 nomenclature changes, the full spectrum of steatotic liver disease, and how metabolic dysfunction drives both MASLD and inflammatory MASH. Allysa reviews practical diagnostic pathways—including non-invasive tests like FIB-4, ELF, FibroScan, and elastography—and highlights why MASLD/MASH should always be evaluated in the broader context of metabolic disorders such as diabetes, obesity, and dyslipidemia. She also outlines the foundation of lifestyle-based treatment, offering real-world communication strategies to help patients succeed with diet, activity, and weight management goals. The talk covers major therapeutic advances, including the first FDA-approved MASH therapy, resmetirom (a THR-β agonist), as well as the growing role of GLP-1 receptor agonists like semaglutide in improving metabolic drivers of liver inflammation and fibrosis. Allysa discusses dosing, titration, safety considerations, expected side effects, and what clinicians should know when co-managing cardiometabolic conditions. She closes with insights on future MASH drug development, combination therapy approaches, and practical pearls for supporting patients through a chronic, complex liver disease.
Related Webcast
Webcast: Comparing F3 and F4 Fibrosis With Kristina Tuesday Werner
October 2025
Tuesday Werner, NP, explains why accurately identifying F3 vs F4 fibrosis is critical in patients with MASLD/MASH. Using real patient case comparisons, she highlights how non-invasive tests like FIB-4, FibroScan, and ELF help determine disease severity, guide treatment, and reduce the need for biopsy. Tuesday reviews how care strategies differ—F3 patients focus on aggressive metabolic control and fibrosis monitoring, while F4 (cirrhosis) requires HCC surveillance, closer specialist follow-up, and potential transplant evaluation.
Watch Now
Webcast: MASLD Pharmacotherapy With Sherona Bau
July 2025
In this dynamic and highly informative session, Sherona Bau, NP, presents a comprehensive overview of pharmacotherapy in MASLD and MASH, breaking down current treatment strategies and emerging therapies for patients with metabolic dysfunction-associated steatotic liver disease. This presentation, part of the MASLD/MASH Community Network, begins by contextualizing the recent nomenclature shift from NAFLD/NASH to MASLD/MASH and its clinical implications. Sherona explores lifestyle intervention targets, including Mediterranean diet, weight loss goals based on fibrosis stage, and the role of GLP-1 and GIP receptor agonists in improving liver health. She highlights the ESSENCE trial results for semaglutide, discusses the only FDA-approved therapy to date—resmetirom (Rezdiffra)—and explains its mechanism of action via thyroid hormone receptor beta activation. The session dives deep into efficacy data from the MAESTRO-NASH trial, side effect profiles, drug–drug interactions, and monitoring recommendations. She also previews a pipeline of promising agents in phase 2 and 3 trials—including tirzepatide (GLP-1/GIP), cotadutide (GLP-1/GR), pemvidutide (GLP-1/GIP), and retatrutide (GLP-1/GIP/GR)—offering insight into what’s next in the evolving treatment landscape. This is a must-watch for hepatology and endocrinology clinicians focused on the future of fatty liver management.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Anna Marie Hefner & Renee Pozza
November 2025
Join Anna Marie Hefner, RN and Renee Pozza, FNP-BC from Southern California Liver & GI Centers for a practical, case-based deep dive into advanced MASLD/MASH—what F3 vs F4 (cirrhosis) really means for staging, treatment, and surveillance. Using a 55-year-old patient scenario, they walk through interpreting FIB-4, FibroScan® (kPa + CAP), ELF, and routine labs; when to add ultrasound + AFP for HCC surveillance, and when to scope for esophageal varices. You’ll hear how they structure follow-up (from biweekly check-ins early to every 3 months), tailor diet and exercise to real-world habits, incorporate GLP-1s for weight and metabolic control, and consider resmetirom for eligible F2–F3 patients (not F4). The session also covers when to escalate to colonoscopy for alternative bleeding sources, and how to alternate US with triphasic CT/MRI in high-risk patients. Perfect for GI/hepatology APPs looking for a clear, actionable framework to manage fibrosis progression and optimize outcomes.
Watch Now
Webcast: MASLD Basics With Anna Marie Hefner & Renee Pozza
October 2025
In this MASLD Community Network session, Anna Hefner, PhD, RN, CPNP, and Renee Pozza, PhD, RN, CNS, FNP-BC, of Southern California GI & Liver Centers break down the new nomenclature for steatotic liver disease (SLD) and what it means for clinical practice. They clarify how to distinguish MASLD from MASH, introduce the overlap category MetALD (metabolic-associated alcohol-related liver disease), and review differential causes of steatosis—from medications and viral hepatitis to genetic and cryptogenic etiologies. The faculty walk through practical primary-care screening with FIB-4, when to escalate with noninvasive tests (FibroScan® CAP/kPa, ELF), and the roles of ultrasound and MRI/MRE—plus when a liver biopsy is still warranted. You’ll learn staging cues (F0–F4), progression risk, who needs closer follow-up, and how to counsel patients on cardiometabolic risk reduction (weight loss, activity, triglyceride/HDL management, blood pressure, glucose). The talk also highlights pediatric considerations, terminology changes to reduce stigma, and tips for consistent waist-circumference measurement and alcohol-intake assessment—equipping PCPs, GI, and hepatology teams to identify fibrosis early and improve outcomes.
Watch Now
Webcast: MASLD vs MetALD With Brian Lam
October 2025
Brian Lam, PA-C, breaks down MetALD—when metabolic dysfunction–associated steatotic liver disease (MASLD) meets alcohol use. Through a real patient case, he reviews risk factors (insulin resistance, triglycerides, BMI), how to interpret FibroScan/Liver Stiffness and CAP, and why alcohol accelerates fibrosis and raises HCC risk. Learn practical screening and counseling tips using AUDIT-C and PEth testing, plus when lifestyle change and therapies for MASH may be considered. Join the MASLD Community Network to connect with APP peers and access more evidence-based education.
Watch Now
Live From GHAPP National: MASH Basics
November 2025
In this session, Tessa Janovsky, PA from Arizona Liver Health, provides a clear, practical overview of the basics of MASH and MASLD, including the updated 2023 steatotic liver disease nomenclature, global prevalence trends, and why MASH is a progressive metabolic liver disease that requires early identification. She reviews high-risk populations, the role of primary care and specialty providers, how to use FIB-4 and non-invasive tests to assess fibrosis, and the importance of recognizing rapid progressors. Using a real clinical case, she highlights how to evaluate patients, rule out other etiologies, and optimize metabolic health—including when to consider pharmacotherapy. A concise, clinic-ready primer for clinicians managing MASLD and MASH.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Edith Johannes
July 2025
Join Edith Johannes, NP from UCLA Health, for a comprehensive and approachable introduction to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)—formerly known as NAFLD—and how to accurately diagnose it. Designed for primary care providers and early learners in hepatology, this session outlines the fundamental criteria for diagnosing MASLD and MASH, the importance of ruling out alternate causes of hepatic steatosis, and the key role of cardio-metabolic risk factors. Edith discusses how to apply non-invasive testing tools such as the FIB-4 score, ELF test, and elastography to determine fibrosis stage, along with guidance on when to consider liver biopsy and refer to hepatology. The presentation also explores the overlap between MASLD and alcohol-related liver disease, addresses the impact of genetic risk factors like PNPLA3 (particularly in Hispanic populations), and reinforces the urgent need for early detection to prevent cirrhosis and liver cancer. With clinical pearls and case-based examples, this session helps clinicians feel confident in evaluating patients for MASLD and navigating next steps for care.
Watch Now
Webcast: MASLD vs MetALD With Lavinia Iordache
September 2025
In this MASLD Community Network session, Lavinia Iordache, PA-C, clarifies the new SLD nomenclature and the distinctions between MASLD and MetALD, then walks through a real-world case (Ashley, 52) to show how to quantify alcohol intake, recognize cardiometabolic risk factors, and stage disease using non-invasive tests (FIB-4, FibroScan/VCTE with CAP, ELF). She explains how even “moderate” alcohol can accelerate fibrosis when metabolic risks are present, why PEth biomarker testing helps uncover under-reported use, and how to triage patients who land in the F3–F4 range. Practical takeaways include culturally sensitive Mediterranean-style nutrition, 5–10% weight-loss goals, tailored exercise, alcohol cessation, and when to consider resmetirom (Rezdiffra) for eligible F2–F3 non-cirrhotic patients. The talk also covers HCC surveillance (and when to prefer CT/MRI over ultrasound in central adiposity) and sets clear pathways for primary care, GI, and hepatology to work in sync.
Watch Now
Webcast: Non-Invasive Testing With Stacie Egan
October 2025
Stacie Egan, FNP-C, discusses how non-invasive testing is transforming the way clinicians evaluate and manage MASLD/MASH. Using a real patient case, she explains how to interpret key tools like FIB-4, ELF, FibroScan (VCTE), and MR elastography to assess liver stiffness, steatosis, and fibrosis severity. Stacie also highlights practical considerations for accurate testing, when to order secondary assessments, and how to combine results with clinical judgment for optimal patient care. Learn how non-invasive diagnostics guide treatment decisions, support early intervention, and improve outcomes in metabolic liver disease.
Watch Now
Webcast: MASLD vs MetALD With Erin Tanner
November 2025
Join Erin Tanner, PA-C for a practical overview of MASLD (metabolic-associated steatotic liver disease) and MetALD, the overlap between metabolic dysfunction and alcohol-related liver injury. Through a real-world case, Erin explains how to interpret FibroScan (kPa/CAP) results, use PEth testing to objectively measure alcohol intake, and recognize how alcohol accelerates fibrosis progression. She reviews risk factors like hypertension, hyperlipidemia, and elevated triglycerides, emphasizing lifestyle interventions, Mediterranean diet, weight loss, and alcohol abstinence to prevent decompensation and liver cancer.
Watch Now